Compare · CLDX vs QUIT

CLDX vs QUIT

Side-by-side comparison of Celldex Therapeutics Inc. (CLDX) and Achieve Life Sciences Inc. (QUIT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CLDX and QUIT operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
  • CLDX is the larger of the two at $2.26B, about 3.3x QUIT ($695.4M).
  • Over the past year, CLDX is up 11.1% and QUIT is up 40.2% - QUIT leads by 29.1 points.
  • CLDX has hit the wire 6 times in the past 4 weeks while QUIT has been quiet.
  • CLDX has more recent analyst coverage (22 ratings vs 0 for QUIT).
PerformanceCLDX+11.11%QUIT+40.21%
2025-11-17+0.00%2026-11-16
MetricCLDXQUIT
Company
Celldex Therapeutics Inc.
Achieve Life Sciences Inc.
Price
-
-
Market cap
$2.26B
$695.4M
1M return
+4.97%
-3.45%
1Y return
+11.11%
+40.21%
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ
NASDAQ
IPO
News (4w)
6
0
Recent ratings
22
0
CLDX

Celldex Therapeutics Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

QUIT

Achieve Life Sciences Inc.

AchieveRx, The Quit Company (Nasdaq: ACHV; QUIT effective November 10, 2026 ; formerly doing business as Achieve Life Sciences, Inc. ) is a late-stage pharmaceutical company with a singular focus on nicotine dependence. AchieveRx's mission is to develop medicine for people who want to quit smoking or vaping. That medicine is cytisinicline, an investigational compound. Three ideas guide the Company: simplicity, science, and second chances, for good.